Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended‐Release Tablet ( NB ‐ ER ) for Weight Maintenance in Adult Patients After a 6‐Month Intensive Behaviour Modification Program Combined With Meal Replacements
Clinical Obesity · 2026-08 · 16 (4)
DOI: 10.1111/cob.70099 ↗At a glance
Randomisierte kontrollierte Studie in Clinical Obesity, published online on 2026-07-21. Written by V Tony Chetty and 6 co-authors. Institution: Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada. Major MEDLINE topics: Bupropion, Naltrexone, Obesity, Behavior Therapy. 29 references. The full text is freely available in PubMed Central. Funded by: Bausch Health.
Abstract (original language)
The prevalence of obesity is increasing worldwide, with approximately nine million people affected in Canada. Obesity is associated with high rates of morbidity and mortality as well as significant healthcare costs and economic burden. The primary therapeutic options for weight maintenance and treatment of weight regain include behaviour modification, lifestyle intervention and pharmacotherapy. This randomised, double‐blind, placebo‐controlled, crossover trial aimed to determine the effect of a fixed‐dose, extended‐release combination of naltrexone and bupropion (NB‐ER) (commonly known as Contrave) on weight maintenance and further weight loss following the intensive portion of a behaviour modification program. The results from this study demonstrate that after an intensive lifestyle intervention program, treatment with NB‐ER for six months prevented weight regain compared to placebo. Additionally, a greater proportion of subjects experienced weight maintenance and less absolute weight regain on NB‐ER compared to placebo, supporting the use of NB‐ER as an effective option for weight maintenance in patients with significant prior weight loss.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada.
- McMaster University, Hamilton, Ontario, Canada.
- Centre for Bariatric Excellence, Guelph General Hospital, Guelph, Ontario, Canada.
- Centre for Bariatric Excellence, Kingston Health Sciences, Kingston, Ontario, Canada.
- The Research Institute of St Joe's, Hamilton, Ontario, Canada.
- Peter Boris Centre for Addictions Research, St Joseph's Healthcare, Hamilton, Ontario, Canada.
ORCID profiles: Suzana Damjanovic, Iris M Balodis
Funding
- Bausch Health
Cite
APA
Chetty, V. T., Denescu, L., Zevin, B., Damjanovic, S., Balodis, I. M., Elsharif, A., & Foster, G. (2026). Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended‐Release Tablet ( NB ‐ ER ) for Weight Maintenance in Adult Patients After a 6‐Month Intensive Behaviour Modification Program Combined With Meal Replacements. Clinical Obesity, 16(4). https://doi.org/10.1111/cob.70099
Vancouver
Chetty VT, Denescu L, Zevin B, Damjanovic S, Balodis IM, Elsharif A, et al. Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended‐Release Tablet ( NB ‐ ER ) for Weight Maintenance in Adult Patients After a 6‐Month Intensive Behaviour Modification Program Combined With Meal Replacements. Clinical Obesity. 2026;16(4). doi:10.1111/cob.70099
BibTeX
@article{Chetty2026,
author = {Chetty, V Tony and Denescu, Liviu and Zevin, Boris and Damjanovic, Suzana and Balodis, Iris M and Elsharif, Adell and Foster, Gary},
title = {Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended‐Release Tablet ( NB ‐ ER ) for Weight Maintenance in Adult Patients After a 6‐Month Intensive Behaviour Modification Program Combined With Meal Replacements},
journal = {Clinical Obesity},
year = {2026},
volume = {16},
number = {4},
doi = {10.1111/cob.70099}
}
EUVIMED